Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Bretazenil | ?96% (HPLC), solid. Group: Fluorescence/luminescence spectroscopy. |  |
| Bretazenil | Bretazenil, also known as Ro 16-6028, is GABA A receptor agonist potentially for the treatment of anxiety disorders. Bretazenil differs from traditional 1,4-benzodiazepines by being a partial agonist and because it binds to α1, α2, α3, α4, α5 and α6 subunit containing GABAA receptor benzodiazepine receptor complexes. 1,4-benzodiazepines bind only to α1, α2, α3 and α5 GABAA benzodiazepine receptor complexes. Uses: Designed for use in research and industrial production. Additional or Alternative Names: Ro 16-6028; Ro 16 6028; Ro16-6028; Ro 166028; Ro 166028; Ro166028; Ro 16-6028/000; Bretazenil. Product Category: Agonists. Appearance: Solid powder. CAS No. 84379-13-5. Molecular formula: C19H20BrN3O3. Mole weight: 418.29. Purity: >97%. IUPACName: tert-butyl (S)-8-bromo-9-oxo-11,12,13,13a-tetrahydro-9H-benzo[e]imidazo[5,1-c]pyrrolo[1,2-a][1,4]diazepine-1-carboxylate. Canonical SMILES: O=C(C1=C([C@@]2([H])N3CCC2)N(C=N1)C4=CC=CC(Br)=C4C3=O)OC(C)(C)C. Density: 1.56 g/cm³. Product ID: ACM84379135. Alfa Chemistry ISO 9001:2015 Certified. |  |
| Bretazenil | Bretazenil. Group: Biochemicals. Grades: Purified. CAS No. 84379-13-5. Pack Sizes: 10mg. US Biological Life Sciences. |  Worldwide |
| Bretazenil | Bretazenil (Ro 16-6028) is a partial agonist at the gamma-aminobutyric acid A (GABA A ) receptor-linked benzodiazepine site. Bretazenil is potent benzodiazepine examined, exhibiting an IC 50 (concentration at which half-maximal inhibition of specific [35S]TBPS binding occurs) of 6.1 nM. Bretazenil shows an EC 50 of 10 nM for recombinant α1β1γ2. Anticonvulsant effects [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: Ro 16-6028. CAS No. 84379-13-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-105056. |  |
| 2-Deoxy-2,2-difluoro-D-erythro-pentonic Acid γ-Lactone 3,5-Dibenzoate | Bretazenil (Ro16-6028) is an imidazopyrrolobenzodiazepine anxiolytic drug that is derived from the benzodiazepine family and was invented in 1988. It is most closely related in structure to the benzodiazepine antagonist flumazenil, although its effects are somewhat different. It is classed as a high-potency benzodiazepine due to its high-affinity binding to benzodiazepine binding sites where it acts as a partial agonist. Its profile as a partial agonist and preclinical trial data suggests that it may have a reduced adverse effect profile. In particular, bretazenil has been proposed to cause a less strong development of tolerance and withdrawal syndrome. Bretazenil differs from traditional 1,4-benzodiazepines by being a partial agonist and because it binds to α1, α2, α3, α4, α5, and α6 subunit-containing GABAA receptor benzodiazepine receptor complexes. 1,4-benzodiazepines bind only to α1, α2, α3 and α5 GABAA benzodiazepine receptor complexes. Group: Salt. Alternative Names: ((2R,3R)-3-(Benzoyloxy)-4,4-difluoro-5-oxotetrahydrofuran-2-yl)methyl benzoate; 2-Deoxyl-2,2-difluoro-D-erythro-pentofuranos-1-ulose-3,5-dibenzoate; 2-Deoxy-2,2-Difluoro-d-Erythro-Pentofuranos-1-Ulose-3,5-Dibenzoate; [(2R,3R)-3-benzoyloxy-4,4-difluoro-5-oxooxolan-2-yl]methyl benzoate; 2-Deoxy-2,2-difluoro-D-erythro-pentonic acid &gamm |  |
| Perfluoro-1-iodohexane | Bretazenil (Ro16-6028) is an imidazopyrrolobenzodiazepine anxiolytic drug that is derived from the benzodiazepine family and was invented in 1988. It is most closely related in structure to the benzodiazepine antagonist flumazenil, although its effects are somewhat different. It is classed as a high-potency benzodiazepine due to its high-affinity binding to benzodiazepine binding sites where it acts as a partial agonist. Its profile as a partial agonist and preclinical trial data suggests that it may have a reduced adverse effect profile. In particular, bretazenil has been proposed to cause a less strong development of tolerance and withdrawal syndrome. Bretazenil differs from traditional 1,4-benzodiazepines by being a partial agonist and because it binds to α1, α2, α3, α4, α5, and α6 subunit-containing GABAA receptor benzodiazepine receptor complexes. 1,4-benzodiazepines bind only to α1, α2, α3 and α5 GABAA benzodiazepine receptor complexes. Uses: Designed for use in research and industrial production. Additional or Alternative Names: Tridecafluoro-1-iodohexane;PERFLUORO-N-HEXYL IODIDE;1-Iodotridecafluorohexane;Perfluorohexyl iodide;1-iodo-tridecafluoro-hexane. Product Category: Heterocyclic Organic Compound. Appearance: Liquid. CAS No. 355-43-1. Molecular formula: C6F13I. Mole weight: 445.95. Purity: 98. Density: 2.063. Product ID: ACM355431. Alfa Chemis | |
| Sodium Oleate | Sodium Oleate. Synonyms: Sodium oleate;oleic acid sodium salt;sodium cis-9-octadecanoate;eunatrol;Lunac SO 90L. CAS No. 143-19-1. Product ID: CDC10-0473. Molecular formula: C18H33NaO2. Category: Cosmetic Surfactants. Product Keywords: Cosmetic Ingredients; Cosmetic Surfactants; Sodium Oleate; CDC10-0473; 143-19-1; C18H33NaO2; Sodium oleate; oleic acid sodium salt; sodium cis-9-octadecanoate; eunatrol; Lunac SO 90L; 205-591-0; MFCD00004438; 143-19-1. Color: White. EC Number: 205-591-0. Physical State: Powder. Storage: -20ºC. Boiling Point: 359.999ºC at 760 mmHg. Melting Point: 232-235ºC(lit.). Density: 0.9 g/cm3. Product Description: Bretazenil (Ro16-6028) is an imidazopyrrolobenzodiazepine anxiolytic drug that is derived from the benzodiazepine family and was invented in 1988. It is most closely related in structure to the benzodiazepine antagonist flumazenil, although its effects are somewhat different. It is classed as a high-potency benzodiazepine due to its high-affinity binding to benzodiazepine binding sites where it acts as a partial agonist. Its profile as a partial agonist and preclinical trial data suggests that it may have a reduced adverse effect profile. In particular, bretazenil has been proposed to cause a less strong development of tolerance and withdrawal syndrome. Bretazenil differs from traditional 1,4-benzodiazepines by being a partial agonist and because it binds to α1, α2, α3, |  |
Our database is helping our users find suppliers everyday.
